Skye Bioscience Inc (NASDAQ: SKYE) kicked off on Monday, up 32.87%% from the previous trading day, before settling in for the closing price of $2.16. Over the past 52 weeks, SKYE has traded in a range of $1.14-$8.99.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 42.99%. While this was happening, its average annual earnings per share was recorded -66.59%. With a float of $17.86 million, this company’s outstanding shares have now reached $30.97 million.
Let’s determine the extent of company efficiency that accounts for 16 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Skye Bioscience Inc (SKYE) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Skye Bioscience Inc is 42.35%, while institutional ownership is 41.37%. The most recent insider transaction that took place on Nov 18 ’24, was worth 97,250. In this transaction Chief Development Officer of this company sold 19,489 shares at a rate of $4.99, taking the stock ownership to the 82,259 shares. Before that another transaction happened on Nov 15 ’24, when Company’s Chief Development Officer sold 85 for $5.55, making the entire transaction worth $472. This insider now owns 101,748 shares in total.
Skye Bioscience Inc (SKYE) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -66.59% per share during the next fiscal year.
Skye Bioscience Inc (NASDAQ: SKYE) Trading Performance Indicators
Take a look at Skye Bioscience Inc’s (SKYE) current performance indicators. Last quarter, stock had a quick ratio of 11.85.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.83, a number that is poised to hit -0.31 in the next quarter and is forecasted to reach -1.40 in one year’s time.
Technical Analysis of Skye Bioscience Inc (SKYE)
Looking closely at Skye Bioscience Inc (NASDAQ: SKYE), its last 5-days average volume was 2.86 million, which is a jump from its year-to-date volume of 0.57 million. As of the previous 9 days, the stock’s Stochastic %D was 40.94%.
During the past 100 days, Skye Bioscience Inc’s (SKYE) raw stochastic average was set at 55.63%, which indicates a significant decrease from 72.81% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 139.95% in the past 14 days, which was lower than the 141.57% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.98, while its 200-day Moving Average is $3.19. However, in the short run, Skye Bioscience Inc’s stock first resistance to watch stands at $3.26. Second resistance stands at $3.66. The third major resistance level sits at $4.13. If the price goes on to break the first support level at $2.39, it is likely to go to the next support level at $1.92. Should the price break the second support level, the third support level stands at $1.52.
Skye Bioscience Inc (NASDAQ: SKYE) Key Stats
The company with the Market Capitalisation of 88.93 million has total of 30,975K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -26,570 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -11,100 K.
